Press Room

Press Clipping / Jan 25, 2019

Fire Services Bureau holds emergency drill at Hovione plant in Taipa

Macau News Agency, January 25, 2019

The Fire Services Bureau held an emergency drill at the Hovione pharmaceutical plant in Taipa, to better strengthen the resilience and coordination of the bureau, and about 150 personnel from both parties participated.

Macau Factory | Hovione

Macau (MNA) – The Fire Services Bureau (CB) on Thursday held an emergency drill at the Hovione PharmaScience Ltd Plant (Hovione) in Taipa, to better strengthen the resilience and coordination of the bureau.

According to a release by the CB, the drill simulated an accident occurring when a worker operating a forklift at the pharmaceutical plant pierced a methanol solvent storage tank and caused a fire.

During the evacuation process of the drill, workers pretended to be injured while the remainder of the staff took safety measures in accordance with the internal contingency plan of the plant, and evacuated all relevant personnel to their emergency meeting point.

When informed of the ‘accident’, the CB dispatched nine emergency vehicles and 37 firefighters to the scene who carried out fire fighting, evacuations, search and rescue, as well as caring for the injured, according to an established plan.

The exercise lasted for about an hour, and a total of 150 personnel from both Hovione and the CB participated in the exercise.

The release states that the drill went smoothly and achieved its intended purpose, and after its completion, a meeting took place between both parties to discuss future exercises in testing their responses.

 

Read complete article at MNA

 

 

Also in the Press Room

See All

Hovione is bringing momentum to the intranasal field after announcing that its lead single-use nasal dry powder device, developed in collaboration with Industrial Design Consultancy Ltd (IDC), is now available for commercial partnerships. The milestone marks the transition from prototype to a fully integrated intranasal drug delivery platform that spans Hovione’s end-to-end partnership capabilities–from API synthesis through advanced formulation and particle engineering to drug product manufacturing, including device supply and advanced analytical tools for nasal performance characterization. The platform’s single-use device is designed to be manufacturable at scale and to leverage existing advanced particle engineering and drug product manufacturing capabilities, a practical advantage that can shorten timelines to clinic and commercialization while reducing development risk and cost. The device’s patented mechanism supports targeted nasal deposition, including access to the upper olfactory region. This enables rapid systemic absorption and potential nose-to-brain delivery pathways that are increasingly important for CNS and emergency-use indications. Beyond the single-use format, Hovione and IDC are advancing a multi-dose variant to broaden applicability across dosing regimens and therapeutic areas. The collaboration is backed by an intellectual property portfolio and initial patent grants, positioning the platform as a turnkey option for pharma partners seeking a single integrated supplier for both drug substance and device. This development arrives as intranasal delivery gains traction for systemic, CNS and rapid-onset therapies. This is precisely the focus of the upcoming 4th Nasal Formulation & Delivery Summit, for which Hovione is a key sponsor. The annual summit unites formulation, delivery and product development leaders to tackle drug-device compatibility, translational preclinical models, and strategies for scalable, regulatory-ready intranasal programs. Hovione’s recent progress will be highly relevant to attendees looking to de-risk nose-to-brain and systemic intranasal programs. Read the full article at News-Medical.net    

Press Clipping

Hovione advances intranasal drug delivery with commercial-ready dry powder platform ahead of 4th Nasal Formulation & Delivery Summit

Jun 01, 2026